Key Points
Idelalisib as upfront therapy for CLL caused an early hepatotoxicity in a subset of primarily younger patients with IGHV-mutated disease.
Multiple lines of evidence suggest that this adverse effect is immune mediated, perhaps through inhibition of regulatory T cells.
Full PDF
Optimizing Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRevolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment ParadigmGuidelines for Diagnosis, Indications for Treatment, Response Assessment and Supportive Management of Chronic Lymphocytic LeukemiaVACCINATIONS FOR PEOPLE WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL/SLL)
Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively
